EverHint – Momentum Swing — Volatile High Beta for Feb 24, 2026 – 6 Signals – Technology Leads (4)

What This Signal Is (Quick)

Volatile High Beta is a momentum swing trading strategy focused on High volatility stocks (60%+) - for risk-tolerant traders.

Signal Type: Breakout (momentum continuation)

What Makes This Signal:

• Stock showing strong momentum near or at highs
• Increased volume confirms institutional interest
• Breaking out or consolidating near resistance
• High volatility stocks (60%+) - for risk-tolerant traders

Ideal For: Risk-tolerant traders comfortable with high volatility and large price swings

Key Criteria:

• Strong RSI momentum (configurable thresholds)

• Volume surge above average

• Price momentum confirmation

• Minimum ADV: $25M+ (varies by variant)

• Earnings buffer: 7 days pre/post earnings

• Variant-specific filters applied

Holding Period: 1-4 weeks
Risk Level: Medium-High

How We Ranked Today

Ranked by composite momentum score (higher = stronger momentum)

📊 Momentum Swing — Volatile High Beta Signals (6 Total)

Ranked by score:

Field Notes

Sector concentration: Technology (4), Healthcare (2)

Insider selling: IBRX (ImmunityBio, Inc., $-1.0M), LASR (nLIGHT, Inc., $-852K), VIR (Vir Biotechnology, Inc., $-132K)

Near-term earnings: IBRX (ImmunityBio, Inc.) report within 7 days. Higher volatility risk.

Data coverage: 50.0% insider, 0.0% congressional, 100.0% earnings, 100.0% analyst, 50.0% news

Peer Analysis

Understanding how these stocks relate to their industry peers:

LASR (nLIGHT, Inc.): Leads 9 peers: HIMX ($7.70, +1.2%), PLAB ($37.99, +2.6%), VECO ($29.36, +2.2%), MXL ($18.25, +1.7%), UCTT ($71.96, +17.2%) | Peer of: AAOI ($56.27, +4.3%), FLYW ($11.24, +5.6%), HIMX ($7.70, +1.2%) and 4 more

UCTT (Ultra Clean Holdings, Inc.): Leads 9 peers: MXL ($18.25, +1.7%), COHU ($30.60, +0.6%), INDI ($3.53, +2.6%), FSLY ($17.67, +3.9%), PLAB ($37.99, +2.6%) | Peer of: AAOI ($56.27, +4.3%), AMPL ($6.83, +5.1%), COHU ($30.60, +0.6%) and 6 more

IBRX (ImmunityBio, Inc.): Leads 9 peers: RCUS ($20.19, +7.1%), DNLI ($21.43, +2.7%), COGT ($39.18, +5.7%), GLPG ($34.36, +1.4%), BEAM ($32.29, +14.0%) | Peer of: AGIO ($30.39, +0.6%), ARDT ($9.62, -0.9%), BEAM ($32.29, +14.0%) and 11 more

AEHR (Aehr Test Systems): Leads 10 peers: SKYT ($28.12, +1.3%), ICHR ($53.58, +4.9%), IMOS ($39.98, +14.0%), AOSL ($22.05, +1.0%), LAES ($3.92, +4.0%) | Peer of: CEVA ($20.13, +7.3%), ICHR ($53.58, +4.9%), IMOS ($39.98, +14.0%) and 2 more

VICR (Vicor Corporation): Leads 10 peers: PLXS ($203.99, +3.3%), OSIS ($297.87, +1.4%), NOVT ($137.44, -3.5%), ST ($38.36, +3.6%), ITRI ($97.84, +2.8%) | Peer of: BMI ($158.34, +1.4%), DXC ($11.92, +0.6%), ESE ($285.56, +3.1%) and 11 more

VIR (Vir Biotechnology, Inc.): Leads 9 peers: MRVI ($3.12, +2.0%), IOVA ($3.78, +30.8%), REPL ($8.36, -0.4%), PRME ($3.83, +14.7%), DNA ($8.86) | Peer of: CDNA ($19.25, +2.5%), CSTL ($29.94, +3.5%), DAWN ($12.02, +2.7%) and 11 more

Recent Headlines

AEHR (Aehr Test Systems)

• Here's Why Aehr Test Systems Rocketed Higher Today (source)
• Aehr Test Systems to Participate in the Susquehanna 15th Annual Technology Conference on February 26, 2026 (source)

IBRX (ImmunityBio, Inc.)

• Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700% (source)
• ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit (source)
• Why ImmunityBio Stock Is Soaring Again Today (source)
• ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth (source)
• ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates (source)
• Undercovered Dozen: Agnico Eagle, Lumentum, ImmunityBio And More (source)
• ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally (source)
• ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients (source)
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX (source)
• ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average (source)
• ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch (source)
• ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up (source)
• ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last? (source)
• Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer (source)
• Why ImmunityBio Stock Is Soaring Today (source)
• What's Behind The Jump In ImmunityBio Stock? (source)
• ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries (source)
• ImmunityBio: The Story Surrounding Anktiva So Far (source)
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX (source)
• New Treatment Modalities Are Reaching Cancers That Resisted Everything Else (source)
• ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia (source)

VIR (Vir Biotechnology, Inc.)

• Vir Biotechnology Announces Proposed Public Offering of Common Stock (source)
• Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish (source)
• These Analysts Boost Their Forecasts On Vir Biotechnology (source)
• Stock Market Today: S&P 500 Futures Slip As Dow, Nasdaq 100 Gain Following Trump's Tariff Threat — Whirlpool, Uber, HP In Focus (UPDATED) (source)
• What's Happening With VIR Stock? (source)
• Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript (source)
• Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates (source)
• Vir Biotech Catapults 65% On A $1.71 Billion Deal With Astellas (source)
• Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results (source)
• Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer (source)
• Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer (source)

Market Context

Broad market indices advanced today, with the Nasdaq leading gains at +0.98%, followed by the S&P 500 at +0.77% and the Dow Jones at +0.71%. This upward trend signals strong risk appetite, favoring momentum-driven strategies that capitalize on continuation in high-beta names. The top sector of Technology aligns well with this leadership, suggesting potential sector rotation toward growth-oriented areas amid positive sentiment.

The VIX declined sharply by 7.91% to 19.56, reflecting reduced volatility and a more stable environment for intraday swings. For a momentum swing strategy targeting volatile high-beta assets, this moderation tempers extreme whipsaws while still providing enough movement—given the VIX's elevated level—for profitable entries and exits. Lower volatility supports trend-following without excessive noise, enhancing signal reliability in a risk-on climate.

Overall, these conditions bolster the six generated signals by amplifying upside potential in trending, high-beta sectors like Technology, though traders should monitor for any VIX rebound that could introduce counter-trend risks.

Vlad's Take (EverHint)

Today's signals: Strong sector concentration in Technology (4 signals) suggests sector-specific rotation. 3 signals showing insider selling warrant caution.

Sharing Call-to-Action

🔍 If this breakdown was useful, feel free to like, share, or subscribe. Every bit of support matters.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/